Getein Biotech (603387.SH) released its performance for the first three quarters, with net profit attributable to shareholders of RMB 232 million, up 44.76% year on year.

Zhitong Finance APP News, Getein Biotech (603387.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 820 million yuan, a year-on-year increase of 8.24%; net profit attributable to the parent company of 232 million yuan, a year-on-year increase of 44.76%; net profit after deducting non-recurring gains and losses of 160 million yuan, a year-on-year increase of 18.79%; basic earnings per share of 0.46 yuan.